Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Starling Oncology, Inc. (STLN)

Starling Oncology sets up $25 million secured revolving credit line maturing August 2029

Neutral Impact 3 of 5 financing Written later

On August 20, 2026, subsidiary Starling Oncology Management, LLC entered a revolving credit agreement with Gemino Healthcare Finance, LLC (d/b/a SLR Healthcare ABL) for up to $25 million. The filing says the company is not required or expected to borrow the full amount, and that it is intended to provide financial flexibility if needed. Shareholders should note the facility is secured by substantially all of the subsidiary's assets and carries a covenant on loan turn days.

Key points

  • Facility of up to $25 million, dated August 20, 2026, maturing August 20, 2029
  • Interest at Term SOFR plus 3.95%, with Term SOFR floored at 2.00% per annum
  • $4,750,000 outstanding as of August 21, 2026 (the filing text reads "$4,750,000 million")
  • Secured by a first-priority security interest in substantially all of the subsidiary's collateral; covenant limits Maximum Loan Turn Days to 35 on a rolling three-month basis

The filing

CompanyStarling Oncology, Inc. (STLN)
Form8-K, current report
Filed with the SECAug 21, 2026, 5:25 PM ET
Accession number0001079973-26-001169

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.